Intravitreal Bevacizumab for Peripapillary
Choroidal Neovascular Membranes P eripapillary choroidal neovascularization (PCNV) can result in significant vision loss due to extension of blood or fluid into the macula. 1, 2 Treatment options for PCNV have included laser photocoagulation, subretinal surgery, and photodynamic therapy. 1, 3, 4 More recently, the use of intravitreal antivascular endothelial growth factor antibodies has emerged as the optimal treatment for macular CNV due to agerelated macular degeneration, presumed ocular histoplasmosis, myopia, angioid streaks, and traumatic choroidal rupture, 5, 6 but clinical trials almost exclusively included patients with subfoveal CNV. The purpose of this study was to review cases of PCNV treated with intravitreal bevacizumab.
Methods. Institutional review board approval was obtained. The Institutional Review Board for Human Subjects Research, University of Iowa, waived informed consent for this retrospective record study. The study was compliant with the Health Insurance Portability and Accountability Act of 1996 and adhered to the tenets of the Declaration of Helsinki. Data from records of patients who received 1.25-mg intravitreal bevacizumab injections at the University of Iowa between September 12, 2008, and March 21, 2011, were retrospectively reviewed. Patients were included if they demonstrated a new, previously untreated PCNV confirmed by fluorescein angiography and subretinal or intraretinal fluid on optical coherence tomography (OCT) and had at least 6 months of follow-up. Patients with vision loss from other non-PCNV causes were excluded. Resolution of PCNV was determined by the absence of intraretinal or subretinal fluid on examination and OCT. Recurrence was defined as new subretinal or intraretinal fluid detected by OCT or hemorrhage detected by ophthalmoscopy.
Results. Twenty eyes from 19 patients met the inclusion criteria. The average patient age was 70.6 years (range, 26-94 years). Causes of PCNV included AMD in 12 eyes, presumed ocular histoplasmosis in 6 eyes, traumatic choroidal rupture in 1 eye, and idiopathic PCNV in 1 eye. Fifteen of 20 eyes had peripapillary fluid on OCT within 1 disc area from the disc without any subfoveal fluid. Only 5 eyes had subfoveal fluid (Table) . Sixteen had peripapillary fluid located temporal to the optic nerve, 3 had it located superiorly, and 1 had it located inferiorly. The follow-up averaged 13.5 months (range, 6-32 months).
An average of 5.6 total injections (range, 2-14 injections) were performed ( Figure Comment. In our study, 17 of 20 eyes (85%) achieved resolution of the fluid after an average of 2.4 intravitreal injections of bevacizumab, and 5 of these had recurrent fluid. Visual acuities improved by an average of 5 letters or 1 line of Snellen visual acuity after an average of 13.5 months of follow-up, and only 1 patient lost vision limited to 1 line (Table) .
Overall, it is our impression that PCNV responds to intravitreal bevacizumab with reduction of retinal fluid and improvement or preservation of vision comparable to other treatment modalities.
1 However, our results are limited by the relatively short term of the study. In PCNV cases of recurrent or incomplete fluid resolution, intravitreal bevacizumab may still shrink lesions prior to other treatment. Further prospective and comparative studies 
Real-time Ophthalmoscopic Findings of Intraophthalmic Artery Chemotherapy in Retinoblastoma

S
uperselective intraophthalmic artery chemotherapy (SSIOAC) has become increasingly popular as a treatment for retinoblastoma. We describe the real-time ophthalmic findings of SSIOAC in a 5-month-old baby treated for bilateral disease.
Methods. After obtaining informed consent, SSIOAC was performed under general anesthesia. The right femoral artery was accessed using a Cathlon 24-gauge needle. A 0.018-inch access guidewire was passed through the needle and the needle was removed. A 4F access sheath was installed and attached to a heparin saline flush system. Heparin (100 IU/kg) was administered. A coaxial system was used. The guide catheter was a 4F glidecath (Terumo Europe NV). A straight Marathon microcatheter (0.51 mm; 1.5F at the distal tip; ev3 Neurovascular) was advanced through the guiding catheter right to the ostium of the ophthalmic artery. Selective angiography of the ophthalmic artery was performed. Every 5 minutes, the position of the catheter was checked under fluoroscopy. The infusion consisted of 2.5 mg of melphalan diluted in 30 mL of saline at a rate of 1 mL/min for 30 minutes.
A Retcam 1300 pediatric lens (Clarity Medical Systems) was used to take serial fundus photographs and videos every 4 minutes. The frequency of the imaging was adjusted according to the findings.
Results. Left Eye. During the infusion, there was visible intermittent pallor of the optic nerve and narrowing and blanching of the retinal vessels ( Figure 1B) . The infusion was interrupted and immediate reperfusion was noticed, allowing for completion of the treatment 
